2invest（2INV）株式概要投資会社である2インベストAGは、主にドイツ国内外のバイオテクノロジー、ライフサイエンス、IT分野の企業やパートナーシップへの投資の取得、保有、管理、売却を行っている。 詳細2INV ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績5/6財務の健全性6/6配当金0/6報酬株価収益率（ 2.4 x） German市場（ 17 x）を下回っています。過去1年間で収益は415.4%増加しました リスク分析過去5年間で収益は年間14%減少しました。 株式の流動性は非常に低い 最新の財務報告は6か月以上前のものである 意味のある時価総額がありません ( €63M )すべてのリスクチェックを見る2INV Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€11.4091.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-20m403m2016201920222025202620282031Revenue €403.4mEarnings €372.7mAdvancedSet Fair ValueView all narratives2invest AG 競合他社DarwinSymbol: MUN:7V0Market cap: €74.4m3D Global BiotechSymbol: TPEX:6808Market cap: NT$2.4bPrestige BioPharmaSymbol: KOSE:A950210Market cap: ₩93.8bSprint BioscienceSymbol: OM:SPRINTMarket cap: SEK 345.0m価格と性能株価の高値、安値、推移の概要2invest過去の株価現在の株価€11.4052週高値€13.6052週安値€10.70ベータ0.201ヶ月の変化0%3ヶ月変化0%1年変化-8.06%3年間の変化58.33%5年間の変化13.32%IPOからの変化-67.13%最新ニュースお知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...最新情報をもっと見るRecent updatesお知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).お知らせ • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.お知らせ • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.お知らせ • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.お知らせ • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.株主還元2INVDE BiotechsDE 市場7D0%0.9%3.2%1Y-8.1%-12.2%2.5%株主還元を見る業界別リターン: 2INV過去 1 年間で-12.2 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 2INVは、過去 1 年間で2.5 % のリターンを上げたGerman市場を下回りました。価格変動Is 2INV's price volatile compared to industry and market?2INV volatility2INV Average Weekly Movementn/aBiotechs Industry Average Movement8.7%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: 2INVの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の2INVのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19975n/a2invest-ag.com投資会社である2invest AGは、主にドイツ国内外のバイオテクノロジー、ライフサイエンス、IT分野の企業やパートナーシップへの投資を取得、保有、管理、販売している。同社は以前は4basebio AGとして知られていたが、2021年1月に2invest AGに社名を変更した。2invest AGはドイツのハイデルベルクに本社を置く。もっと見る2invest AG 基礎のまとめ2invest の収益と売上を時価総額と比較するとどうか。2INV 基礎統計学時価総額€62.87m収益（TTM）€25.93m売上高(TTM)€28.07m2.4xPER（株価収益率2.2xP/Sレシオ2INV は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計2INV 損益計算書（TTM）収益€28.07m売上原価€0売上総利益€28.07mその他の費用€2.14m収益€25.93m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）4.70グロス・マージン100.00%純利益率92.39%有利子負債／自己資本比率0%2INV の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/05 18:32終値2026/01/06 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋2invest AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Andrew Murray DarleyCavendishMark BrewerCavendishChristian OrqueraFirst Berlin Equity Research GmbH1 その他のアナリストを表示
お知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.
New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).
お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.
New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).
お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.
分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...
お知らせ • Apr 212invest AG, Annual General Meeting, May 27, 20262invest AG, Annual General Meeting, May 27, 2026, at 12:00 W. Europe Standard Time.
New Risk • Apr 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 95% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (95% accrual ratio). Minor Risk Market cap is less than US$100m (€69.6m market cap, or US$79.2m).
お知らせ • Mar 042invest AG, Annual General Meeting, Apr 11, 20252invest AG, Annual General Meeting, Apr 11, 2025, at 15:00 W. Europe Standard Time.
New Risk • Feb 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€69.6m market cap, or US$72.7m).
お知らせ • May 082invest AG, Annual General Meeting, Jun 12, 20242invest AG, Annual General Meeting, Jun 12, 2024, at 11:00 W. Europe Standard Time.
分析記事 • May 01We Think 2invest's (ETR:2INV) Robust Earnings Are ConservativeEven though 2invest AG's ( ETR:2INV ) recent earnings release was robust, the market didn't seem to notice. Our...
New Risk • Mar 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€2.4m revenue, or US$2.7m). Market cap is less than US$100m (€45.4m market cap, or US$49.2m).
New Risk • Jun 30New major risk - Revenue and earnings growthEarnings have declined by 6.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.6% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€36.5m market cap, or US$39.7m).
お知らせ • Apr 152invest AG to Report Fiscal Year 2021 Results on Apr 19, 20222invest AG announced that they will report fiscal year 2021 results on Apr 19, 2022
Is New 90 Day High Low • Mar 15New 90-day low: €11.52The company is down 30% from a price of €16.43 on 15 December 2020. Underperformed the German market, which is up 10.0% over the last 90 days. Lagged the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Feb 22New 90-day low: €1.40The company is down 23% from its price of €1.82 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 04New 90-day low: €1.60The company is down 19% from its price of €1.98 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.
お知らせ • Dec 314basebio AG Announces Board Changes4basebio AG announced that agreed that the two members of the Management Board, Dr. Heikki Lanckriet and Mr. David Roth, will each resign from the Management Board of 4basebio AG with effect from December 30, 2020. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021. The Supervisory Board would like to thank Dr. Heikki Lanckriet and Mr. David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr. Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.
お知らせ • Dec 104basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business.The Board of Directors of 4basebio AG (XTRA:4BSB) announced the spin-off of unknown majority stake in Genomics and DNA manufacturing business on August 17, 2020. A spin-off of Genomics and DNA manufacturing business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalized from the existing cash of 4basebio AG. The management board of 4basebio AG would join the Board of the spin-off and assume responsibility for the day to day operation of this organization. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The deal is subject to an ongoing legal and tax review. On November 3, 2020, the shareholders of 4basebio AG approved the transaction. The intention is to complete this core process by December 31, 2020. 4basebio AG (XTRA:4BSB) completed the spin-off of Genomics and DNA manufacturing business on December 8, 2020.
お知らせ • Dec 024basebio AG Announces Board Changes4basebio AG announced that the previous member of the company's Supervisory Board, Mr. Hansjörg Plaggemars, resigned from his office as a member of the company's Supervisory Board by letter dated 29 November 2020. Mr. Alexander Link, who was elected as a substitute member of the Supervisory Board during the Extraordinary General Meeting of the Company on 3 November 2020, thus automatically takes over the Supervisory Board mandate from Mr. Plaggemars. In addition, the Supervisory Board appointed Hansjörg Plaggemars to the Executive Management Board of 4basebio AG at its meeting. Mr. Plaggemars will become the third member of the Executive Management Board alongside Dr Heikki Lanckriet and David Roth.
Is New 90 Day High Low • Oct 22New 90-day low: €1.95The company is down 8.0% from its price of €2.12 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.
